New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GSK;GSK;FOLD;FOLD;CBST;CBST From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
11:09 EDTFOLDOptions with increasing implied volatility
Subscribe for More Information
10:01 EDTFOLDOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:07 EDTFOLDAmicus initiated with a Buy at Chardan
Subscribe for More Information
May 26, 2015
08:14 EDTGSKBoston Biotech Conferences to hold a conference
Subscribe for More Information
07:06 EDTFOLDAmicus granted Accelerated Assessment by EMA
Amicus Therapeutics announced that the Committee for Medicinal Products for Human Use, or CHMP. of the European Medicines Agency, or EMA, has granted Accelerated Assessment to the oral small molecule pharmacological chaperone migalastat HCl monotherapy for Fabry patients who have amenable genetic mutations. Migalastat is the first investigational Fabry drug to be granted Accelerated Assessment.
May 22, 2015
10:52 EDTGSKJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
May 21, 2015
07:37 EDTGSKPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 20, 2015
07:46 EDTGSKDeutsche Bank positive on potential Pfizer, GSK merger
Deutsche Bank analyst Gregg Gilbert believes a large foreign deal for Pfizer (PFE) may make sense and says a buyout of GlaxoSmithKline (GSK) could be "materially" accretive to earnings while improving the company's tax situation over time. Gilbert assumes a $60 per share buyout price for GlaxoSmithKline in a research note this morning titled "Introducing 'PfizerKline'". The stock closed yesterday up 2c to $44.68. Gilbert reiterates a Buy rating on Pfizer with a $41 price target. Shares ended yesterday up 23c to $34.21.
May 19, 2015
09:25 EDTGSKGlaxoSmithKline asthma drug overused, risks underappreciated, ProPublica says
Subscribe for More Information
06:55 EDTGSKGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use